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Supplementary Table S2. Dosing details and day of the first dose of immunomodulatory drug(s) 
used. 
 
Drug Variable Number of patients 
Tocilizumab   
Dose <400 mg 1 
400 mg 10 
600 mg 70 
>600 mg 3 
Not available 4 
Number of doses 1 38 
2 34 
≥3 12 
Not available 4 
Day of first dose Day 0 43 
Day 1 29 








Dose (methylprednisolone or 
equivalent) 
<40 mg/day 11 
40-80 mg/day 84 
81-125 mg/day 28 
Day of first dose Day 0 61 
Day 1 35 
Day 2 21 
Corticosteroids, pulse dose   
Drug used Methylprednisolone 56 
Dexamethasone 20 
Prednisone 2 
Dose (methylprednisolone or 
equivalent) 
250-499 mg/day 63 
≥500 mg/day 13 




Continuation with low doses 73 
Day of first dose Day 0 39 
Day 1 28 
Day 2 11 





Table S3A. Demographic and clinical data of propensity score-matched patients receiving no 
treatment or tocilizumab. Data are number (proportion) of patients with known exposure to the 
variable except where specified.  




Age, median years (IQR) 68 (56-74) 68 (57-73) 
Female gender 25 (23.6) 15 (28.3) 
Caucasian ethnicity 94 (88.7) 48 (90.6) 
Comorbidities   
Cardiac disease 21 (19.8) 8 (15.1) 
Hypertension 43 (40.6) 23 (43.4) 
Chronic pulmonary disease 11 (10.4) 4 (7.5) 
Severe chronic renal insufficiency 3 (2.8) 0 
Liver cirrhosis 1 (0.9) 0 
Malignancy 4 (3.7) 1 (1.9) 
HIV infection 0 1 (1.9) 
Obesity 10 (9.4) 5 (9.4) 
Diabetes mellitus 20 (18.9) 10 (18.9) 
Dementia 6 (5.7) 1 (1.9) 
Admission data   
Bilateral infiltrates in thorax radiography 87 (82.1) 45 (84.9) 
Lymphocytes/µL, mean (SD) 1283 (1704) 1000 (876) 
LDH in U/L, mean (SD) 395 (166) 382 (150) 
Antiviral treatment before day 0   
Lopinavir/ritonavir 80 (75.5) 46 (86.8) 
Hydroxycloroquine 98 (92.5) 52 (98.1) 
Remdesivir 1 (0.9) 0 
Azithromycin 69 (65.1) 37 (69.8) 
Data on day 0   
Median days of symptoms (IQR) 8 (7-12) 10 (7-12) 
Fever 53 (50) 26 (49.1) 
Worsening in oxygen requirements 91 (85.8) 46 (86.8) 
Ferritin >2000 ng/mL 24 (22.6) 10 (18.9) 
D-dimers >1500 µg/mL 52 (49.1) 29 (54.7) 
IL6 >50 pg/mL 49 (46.2) 22 (41.5) 
Oxygen support at day -1   
   High-flow nasal cannula 4 (3.8) 2 (3.8) 
   Non-invasive mechanical ventilation 1 (0.9) 1 (1.9) 
Low molecular weight heparin   
   Prophylactic dose 76 (73.1) 39 (76.5) 





Table S3B. Demographic and clinical data of propensity score-matched patients receiving no 
treatment or corticosteroids, intermediate-high dose. Data are number (proportion) of patients 
with known exposure to the variable except where specified. 






Age, median years (IQR) 71 (61-77) 70 (61-75) 
Female gender 52 (32.0) 24 (29.6) 
Caucasian ethnicity 155 (95.0) 81 (100) 
Comorbidities   
Cardiac disease 33 (20.3) 15 (18.5) 
Hypertension 90 (55.5) 42 (51.9) 
Chronic pulmonary disease 22 (13.5) 12 (14.8) 
Severe chronic renal insufficiency 4 (2.4) 3 (3.7) 
Liver cirrhosis 3 (1.8) 1 (1.2) 
Malignancy 7 (4.3) 5 (6.1) 
HIV infection 0 0 
Obesity 25 (15.4) 11 (13.6) 
Diabetes mellitus 40 (24.6) 21 (25.9) 
Dementia 9 (5.5) 3 (3.7) 
Admission data   
Bilateral infiltrates in thorax radiography 137 (84.5) 69 (85.2) 
Lymphocytes/µL, mean (SD) 978 (608) 1118 (776) 
LDH in U/L, mean (SD) 383 (151) 296 (161) 
Antiviral treatment before day 0   
Lopinavir/ritonavir 120 (74.0) 64 (79.0) 
Hydroxycloroquine 148 (91.3) 75 (92.6) 
Remdesivir 2 (1.2) 0 
Azithromycin 102 (62.9) 54 (66.7) 
Data on day 0   
Median days of symptoms (IQR) 9 (1-13) 10 (7-13) 
Fever 84 (51.8) 47 (58.0) 
Worsening in oxygen requirements 118 (72.8) 59 (72.8) 
Ferritin >2000 ng/mL 43 (26.5) 25 (30.9) 
D-dimers >1500 µg/mL 80 (49.2) 42 (51.9) 
IL6 >50 pg/mL 54 (33.3) 27 (33.3) 
Oxygen support at day -1   
   High-flow nasal cannula 6 (3.7) 1 (1.2) 
   Non-invasive mechanical ventilation 0 2 (2.5) 
Low molecular weight heparin   
   Prophylactic dose 119 (73.4) 61 (75.3) 





Table S3C. Demographic and clinical data of propensity score-matched patients receiving no 
treatment or corticosteroids, pulse dose. Data are number (proportion) of patients with known 
exposure to the variable except where specified. 





Age, median years (IQR) 70 (61-78) 71 (58-77) 
Female gender 27 (24.1) 14 (25.0) 
Caucasian ethnicity 104 (92.9) 54 (96.4) 
Comorbidities   
Cardiac disease 12 (10.7) 10 (17.9) 
Hypertension 51 (45.5) 30 (53.6) 
Chronic pulmonary disease 13 (11.6) 7 (12.5) 
Severe chronic renal insufficiency 5 (4.5) 3 (5.4) 
Liver cirrhosis 2 (1.8) 1 (1.8) 
Malignancy 8 (7.1) 5 (8.9) 
HIV infection 0 0 
Obesity 8 (7.1) 4 (7.1) 
Diabetes mellitus 20 (17.9) 9 (16.1) 
Dementia 6 (5.4) 0 
Admission data   
Bilateral infiltrates in thorax radiography 91 (81.3) 46 (82.1) 
Lymphocytes/µL, mean (SD) 932 (432) 1348 (2035) 
LDH in U/L, mean (SD) 401 (163) 367 (123) 
Antiviral treatment before day 0   
Lopinavir/ritonavir 81 (72.3) 44 (78.6) 
Hydroxycloroquine 106 (94.6) 54 (96.4) 
Remdesivir 2 (1.8) 0 
Azithromycin 69 (61.6) 33 (58.9) 
Data on day 0   
Median days of symptoms (IQR) 8 (6-11) 10 (6-12) 
Fever 53 (47.3) 27 (48.2) 
Worsening in oxygen requirements 98 (87.5) 48 (85.7) 
Ferritin >2000 ng/mL 40 (35.7) 19 (33.9) 
D-dimers >1500 µg/mL 58 (51.8) 29 (51.8) 
IL6 >50 pg/mL 30 (26.8) 13 (23.2) 
Oxygen support at day -1   
   High-flow nasal cannula 1 (0.9) 0 
   Non-invasive mechanical ventilation 0 1 (1.8) 
Low molecular weight heparin   
   Prophylactic dose 84 (77.1) 41 (73.2) 





Table S3D. Demographic and clinical data of propensity score-matched patients receiving no 
treatment or combination therapy. Data are number (proportion) of patients with known exposure 
to the variable except where specified. 





Age, median years (IQR) 68 (56-74) 68 (58-76) 
Female gender 40 (26.6) 18 (24.0) 
Caucasian ethnicity 137 (91.3) 69 (92.0) 
Comorbidities   
Cardiac disease 21 (14.4) 14 (18.7) 
Hypertension 71 (47.3) 38 (50.7) 
Chronic pulmonary disease 16 (10.6) 8 (10.7) 
Severe chronic renal insufficiency 1 (0.6) 1 (1.3) 
Liver cirrhosis 0 0 
Malignancy 5 (3.3) 1 (1.3) 
HIV infection 0 0 
Obesity 21 (14.0) 13 (17.3) 
Diabetes mellitus 27 (18.0) 18 (24.0) 
Dementia 0 0 
Admission data   
Bilateral infiltrates in thorax radiography 122 (81.3) 62 (82.7) 
Lymphocytes/µL, mean (SD) 1022 (684) 983 (593) 
LDH in U/L, mean (SD) 392 (146) 382 (149) 
Antiviral treatment before day 0   
Lopinavir/ritonavir 112 (74.6) 55 (73.3) 
Hydroxycloroquine 142 (94.6) 70 (93.3) 
Remdesivir 3 (2.0) 0 
Azithromycin 100 (66.6) 58 (77.3) 
Data on day 0   
Median days of symptoms (IQR) 9 (8-12) 10 (8-12) 
Fever 80 (53.3) 38 (50.7) 
Worsening in oxygen requirements 118 (78.6) 62 (82.7) 
Ferritin >2000 ng/mL 45 (26.6) 20 (26.7) 
D-dimers >1500 µg/mL 68 (45.3) 38 (50.7) 
IL6 >50 pg/mL 58 (38.6) 27 (36.0) 
Oxygen support at day -1   
   High-flow nasal cannula 6 (4.0) 3 (4.0) 
   Non-invasive mechanical ventilation 4 (2.6) 4 (5.3) 
Low molecular weight heparin   
   Prophylactic dose 106 (70.6) 57 (76.0) 




Supplementary Figure S1.  Probability of remaining event- free (intubation or death) according to 
the different treatments used, in comparison with no treatment adjusted by the inverse probability 
of treatment weight. A) Tocilizumab. B) High-dose steroids. Low-dose steroids and combination 





Supplementary Figure S2. Probability of being alive according to the different treatments used, in comparison with no treatment (crude analyses). A) Tocilizumab. 




Supplementary Figure S3. Probability of being alive according to the different treatments used, in 
comparison with no treatment adjusted by the inverse probability of treatment weight. A) 
Tocilizumab. B) Corticosteroids, intermediate-high dose. Corticosteroidsm pulse dose and 
combination therapy were not included as Cox regression could not be applied. 
 
